778 research outputs found

    Reflections on the Utility of the Retina as a Biomarker for Alzheimer's Disease: A Literature Review.

    Get PDF
    As a part of the central nervous system, the retina may reflect both physiologic processes and abnormalities related to diseases of the brain. Indeed, a concerted effort has been put forth to understand how Alzheimer's disease (AD) pathology may manifest in the retina as a means to assess the state of the AD brain. The development and refinement of ophthalmologic techniques for studying the retina in vivo have produced evidence of retinal degeneration in AD diagnosed patients. In this review, we will discuss retinal imaging techniques implemented to study the changes in AD retina as well as highlight the recent efforts made to correlate such findings to other clinical hallmarks of AD to assess the viability of the retina as a biomarker for AD

    Regression of ranked responses when raw responses are censored

    Full text link
    We discuss semiparametric regression when only the ranks of responses are observed. The model is Yi=F(xi′β0+εi)Y_i = F (\mathbf{x}_i'{\boldsymbol\beta}_0 + \varepsilon_i), where YiY_i is the unobserved response, FF is a monotone increasing function, xi\mathbf{x}_i is a known p−p-vector of covariates, β0{\boldsymbol\beta}_0 is an unknown pp-vector of interest, and εi\varepsilon_i is an error term independent of xi\mathbf{x}_i. We observe {(xi,Rn(Yi)):i=1,…,n}\{(\mathbf{x}_i,R_n(Y_i)) : i = 1,\ldots ,n\}, where RnR_n is the ordinal rank function. We explore a novel estimator under Gaussian assumptions. We discuss the literature, apply the method to an Alzheimer's disease biomarker, conduct simulation studies, and prove consistency and asymptotic normality.Comment: 33 pages, 6 figure

    Cloud condensation nucleus (CCN) behavior of organic aerosol particles generated by atomization of water and methanol solutions

    Get PDF
    Cloud condensation nucleus (CCN) experiments were carried out for malonic acid, succinic acid, oxalacetic acid, DL-malic acid, glutaric acid, DL-glutamic acid monohydrate, and adipic acid, using both water and methanol as atomization solvents, at three operating supersaturations (0.11%, 0.21%, and 0.32%) in the Caltech three-column CCN instrument (CCNC3). Predictions of CCN behavior for five of these compounds were made using the Aerosol Diameter Dependent Equilibrium Model (ADDEM). The experiments presented here expose important considerations associated with the laboratory measurement of the CCN behavior of organic compounds. Choice of atomization solvent results in significant differences in CCN activation for some of the compounds studied, which could result from residual solvent, particle morphology differences, and chemical reactions between the particle and gas phases. Also, significant changes in aerosol size distribution occurred after classification in a differential mobility analyzer (DMA) for malonic acid and glutaric acid. Filter analysis of adipic acid atomized from methanol solution indicates that gas-particle phase reactions may have taken place after atomization and before the methanol was removed from the sample gas stream. Careful consideration of these experimental issues is necessary for successful design and interpretation of laboratory CCN measurements

    Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.

    Get PDF
    INTRODUCTION:We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS:This was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0.25% human albumin (n = 121) administered every 2 weeks ± 7 days for 18 months. RESULTS:Elevated risk ratios of IGIV versus placebo included chills (3.85) in 9.5% of IGIV-treated subjects (all doses), compared to 2.5% of placebo-treated subjects, and rash (3.08) in 15.3% of IGIV-treated subjects versus 5.0% of subjects treated with placebo. Subjects in the highest IGIV dose group had the lowest proportion of SAEs considered related to product (2 of 127 [1.6%]). Subjects treated with IGIV experienced a lower rate of respiratory and all other infections compared to placebo. DISCUSSION:IGIV-treated subjects did not experience higher rates of renal failure, lung injury, or thrombotic events than the placebo group. There were no unexpected safety findings. IGIV was well tolerated throughout 18 months of treatment in subjects aged 50-89 years
    • …
    corecore